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Implementation of dual 
maternal HIV-Syphilis 
testing: The devil is in 
the details
We read with interest the Article by 
Patricia Rodriguez and colleagues1 
published in The Lancet Global Health in 
which a rigorous and comprehensive 
model showed that dual testing for 
HIV and syphilis is cost-saving for use 
at the first antenatal care visit and cost-
effective during late antenatal care.
In collaboration with multiple 
partners, we have supported the 
adoption and scale-up of dual HIV 
and syphilis testing for pregnant 
women through advocacy, workshops, 
webinars, and country-specific 
technical assistance. Our experience 
has shown that even with political 
will, WHO normative guidance, three 
WHO prequalified tests, a favourable 
funding environment, and evidence 
of cost-effectiveness and efficiency, 
implementation of the dual test 
has been hampered by five crucial 
operational challenges.
First, the need for a holistic 
approach between historically siloed 
HIV and sexually transmitted disease 
programmes with coordinated policies 
and funding streams so that pregnant 
women do not face user fees for HIV 
and syphilis testing.
Second, at the national level, use 
of the dual test in antenatal care 
necessitates development of two HIV 
testing algorithms (one for pregnant 
women and one for everyone else). 
The continued need for standalone 
HIV and syphilis rapid tests (for women 
already diagnosed with syphilis or 
HIV) mitigates potential supply chain 
simplification advantages of the dual 
test.
Third, because the dual test is not 
recommended for women with 
known HIV infection, separate clinical 
workflows are required based on HIV 
status at first antenatal care visit, 
which makes patient pathways more 
complicated for providers.
Fourth, data for HIV and syphilis 
testing and treatment are captured 
in separate systems, necessitating 
substantial revision of monitoring 
tools and processes. Finally, efforts to 
launch HIV self-testing and recency 
testing might supplant dual testing 
roll-out.
Countries recognise the benefits of 
dual testing and there is substantial 
interest to adopt the process. As 
countries move to adopt the 2019 
WHO testing guidelines, it is an 
opportune time to address these dual 
test implementation issues. Global 
stakeholders should collaborate to 
support comprehensive and robust 
roll-out plans to expedite scale-up and 
mitigate operational hurdles.
WHO estimated 355 000 adverse 
pregnancy outcomes occur annually 
due to syphilis, two-thirds of which 
result in stillbirth or neonatal deaths. 
In 2016, we wrote about the need 
to use the dual HIV-syphilis test to 
prevent these tragic outcomes.2 
4 years and the loss of more than 
1 million babies later, inaction is not 
acceptable. We must now resolve these 
implementation issues to save lives.
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